Double-blind RCTs on Magnesium Bisglycinate NMDA/GABA receptor modulation and nocturnal cortisol reduction, antidepressant remission meta-analyses, SAMe augmentation trials, and optical smartwatch HRV validation studies. Explore 674 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Contrary to expectation, smoking abstinence among smokers with a history of major depression did not lead to increase in depression, anxiety or suicide ideation; however, failed quit attempts did.
Comparative efficacy of c-pharm early and late strategies in providing improved protection against post-ECT relapse of depression needs to be further explored.
Side effects were generally mild to moderate and similar between treatment groups.
Melatonin treatment in persons with ID and chronic trouble sleeping decreases daytime challenging behaviour, probably by improving sleep maintenance or by improving circadian melatonin rhythmicity.
High CAR was associated with an impairment of the effect of bright light therapy.
The present study indicates that zaleplon increases nocturnal melatonin secretion without increasing daytime melatonin levels.
Results of short-term, all-duration, and psychiatric studies analyses, as well as age-group analyses, performed in accordance with the FDA-specified search strategy, show no significant increase in suicidality risk in adult...
Test accuracy in repeated validation studies of the same screening test is variable, suggesting an underlying heterogeneity in either the clinical presentation of obstructive sleep apnea or the measured clinical elements of...
Intensive combined treatment provides superior acute and long-term effects over standard treatment in chronically depressed inpatients.
Parents were satisfied with these results.
Findings from this pilot project suggest that bupropion XL may be useful in treating GAD.
1.25+/-1.09, p=0.569), or HAM-A scores at endpoint (3.30+/-2.89 vs.
The use of variable dosing in PMED increases the effectiveness of treatment.
Only response inhibition, a fundamental executive function, predicted poor treatment response to antidepressant medication.
These results demonstrate enhancement of the antidepressant effect of sertraline by concurrent treatment with liothyronine without a significant increase in adverse effects.
In depressed patients with persistent symptoms after an initial trial of sertraline, addition of atomoxetine did not improve response more than placebo.
Melatonin advanced circadian rhythms of sleep-wake and endogenous melatonin and enhanced total time asleep in children with ADHD and chronic sleep onset trouble sleeping; however, no effect was found on problem behavior,...
Sertraline is an effective antidepressant for postmenopausal women with MDD.
Bupropion treatment was associated with significant improvements in depression and anxiety symptoms in asthma patients.
The DAS is a reliable measure of 5 delusional domains.
All treatments led to a reduction in depression, but the advantages of a combined approach were not evident.
Aside from adverse effects of venlafaxine XR on sexual function, both treatments were reasonably well tolerated.
Bright light did not have a sustained effect after discontinuation.
Stimulation of the central monoaminergic system with the antidepressants bupropion and sertraline did not enhance the retrieval of long-term emotional memories in man.
Trouble sleeping was the most important factor compromising the success of OSAS treatment with IOMRAs, and the isolated presence of gastric, neurological and rheumatic diseases, but especially their combination, reduces the...
Combined sleep hygiene and melatonin was a safe and effective treatment for initial trouble sleeping in children with ADHD taking stimulant medication.
Despite the absence of motor complications, the pramipexole recipients showed improvement on the Unified Parkinson's Disease Rating Scale (UPDRS) motor subscore.
After unsuccessful treatment with an SSRI, approximately one in four patients had a full symptom relief of symptoms after switching to another antidepressant.
Augmentation of citalopram with either sustained-release bupropion or buspirone appears to be useful in actual clinical settings.
According to the Sex FX scale, a significant difference in antidepressant-related sexual dysfunction was detected in men, but not women, during treatment with bupropion SR or paroxetine.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
